Sonrai and Plectonic team up to fast-track precision immunotherapy development
AI precision-medicine company Sonrai Analytics and German biotech Plectonic Biotech have entered a partnership to accelerate the development of next-generation immunotherapies using Plectonic’s LOGIBODY platform.
The alliance will use Sonrai’s AI-powered platform to analyze single-cell RNA sequencing and proteomic datasets, aiming to identify specific antigen combinations that distinguish tumors from healthy tissue.
According to Sonrai founder Darragh McArt, the project highlights the role of AI in solving “complex biomedical challenges,” with the goal of bringing safer, more effective cancer treatments to market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze